Make each MenACWY vaccination a MENVEO moment.
Help protect appropriate patients with a primary and booster dose of MENVEO.
|MENVEO Dosing for Younger and Older Adolescents1|
|Primary Vaccination||Booster Vaccination|
|Single dose in adolescents and adults aged 11 through 55 years||Single booster dose may be administered to individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose of a MenACWY vaccine|
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons aged 2 months through 55 years. MENVEO does not prevent N. meningitidis serogroup B infections.
Vaccination may not protect all recipients.
Hear a first-hand account from a physician who has seen meningococcal disease in the pediatric ICU.
Learn how to implement MENVEO into your practice and how to reconstitute and administer MENVEO.